REDUCE-IT USA Article Swipe
Deepak L. Bhatt
,
Michael Miller
,
Eliot A. Brinton
,
Terry A. Jacobson
,
Philippe Gabríel Steg
,
Steven B. Ketchum
,
Ralph T. Doyle
,
Rebecca A. Juliano
,
Lixia Jiao
,
Craig Granowitz
,
Jean‐Claude Tardif
,
Brian Olshansky
,
Mina K. Chung
,
C. Michael Gibson
,
Robert P. Giugliano
,
Matthew J. Budoff
,
Christie M. Ballantyne
·
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1161/circulationaha.119.044440
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1161/circulationaha.119.044440
Background: Some trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States. Methods: REDUCE-IT randomized 8179 statin-treated patients with qualifying triglycerides ≥135 and 40 and ≤100 mg/dL and a history of atherosclerosis or diabetes mellitus to icosapent ethyl 4 g/d or placebo. The primary composite end point was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary composite end point was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. A hierarchy was prespecified for examination of individual and composite end points. Results: A total of 3146 US patients (38.5% of the trial) were randomized and followed for a median of 4.9 years; 32.3% were women and 9.7% were Hispanic. The primary composite end point occurred in 24.7% of placebo-treated patients versus 18.2% of icosapent ethyl-treated patients (hazard ratio [HR], 0.69 [95% CI, 0.59–0.80]; P =0.000001); the key secondary composite end point occurred in 16.6% versus 12.1% (HR, 0.69 [95% CI, 0.57–0.83]; P =0.00008). All prespecified hierarchical end points were meaningfully and significantly reduced, including cardiovascular death (6.7% to 4.7%; HR, 0.66 [95% CI, 0.49–0.90]; P =0.007), myocardial infarction (8.8% to 6.7%; HR, 0.72 [95% CI, 0.56–0.93]; P =0.01), stroke (4.1% to 2.6%; HR, 0.63 [95% CI, 0.43–0.93]; P =0.02), and all-cause mortality (9.8% to 7.2%; HR, 0.70 [95% CI, 0.55–0.90]; P =0.004); for all-cause mortality in the US versus non-US patients, P interaction =0.02. Safety and tolerability findings were consistent with the full study cohort. Conclusions: Whereas the non-US subgroup showed significant reductions in the primary and key secondary end points, the US subgroup demonstrated particularly robust risk reductions across a variety of individual and composite end points, including all-cause mortality. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01492361.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1161/circulationaha.119.044440
- https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044440
- OA Status
- bronze
- Cited By
- 132
- References
- 32
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2985476501
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2985476501Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1161/circulationaha.119.044440Digital Object Identifier
- Title
-
REDUCE-IT USAWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2019Year of publication
- Publication date
-
2019-11-11Full publication date if available
- Authors
-
Deepak L. Bhatt, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Philippe Gabríel Steg, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Craig Granowitz, Jean‐Claude Tardif, Brian Olshansky, Mina K. Chung, C. Michael Gibson, Robert P. Giugliano, Matthew J. Budoff, Christie M. BallantyneList of authors in order
- Landing page
-
https://doi.org/10.1161/circulationaha.119.044440Publisher landing page
- PDF URL
-
https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044440Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044440Direct OA link when available
- Concepts
-
Medicine, Hazard ratio, Myocardial infarction, Internal medicine, Placebo, Unstable angina, Stroke (engine), Diabetes mellitus, Clinical endpoint, Cardiology, Randomized controlled trial, Confidence interval, Endocrinology, Alternative medicine, Mechanical engineering, Engineering, PathologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
132Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 11, 2024: 16, 2023: 17, 2022: 23, 2021: 25Per-year citation counts (last 5 years)
- References (count)
-
32Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2985476501 |
|---|---|
| doi | https://doi.org/10.1161/circulationaha.119.044440 |
| ids.doi | https://doi.org/10.1161/circulationaha.119.044440 |
| ids.mag | 2985476501 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/31707829 |
| ids.openalex | https://openalex.org/W2985476501 |
| fwci | 23.66566944 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000368 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Aged |
| mesh[1].qualifier_ui | Q000187 |
| mesh[1].descriptor_ui | D008078 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | drug effects |
| mesh[1].descriptor_name | Cholesterol, LDL |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D004311 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Double-Blind Method |
| mesh[3].qualifier_ui | Q000031 |
| mesh[3].descriptor_ui | D015118 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | analogs & derivatives |
| mesh[3].descriptor_name | Eicosapentaenoic Acid |
| mesh[4].qualifier_ui | Q000494 |
| mesh[4].descriptor_ui | D015118 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | pharmacology |
| mesh[4].descriptor_name | Eicosapentaenoic Acid |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D005260 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Female |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D006801 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Humans |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D019161 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D008297 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Male |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D008875 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Middle Aged |
| mesh[10].qualifier_ui | Q000188 |
| mesh[10].descriptor_ui | D009203 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | drug therapy |
| mesh[10].descriptor_name | Myocardial Infarction |
| mesh[11].qualifier_ui | Q000401 |
| mesh[11].descriptor_ui | D009203 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | mortality |
| mesh[11].descriptor_name | Myocardial Infarction |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D012307 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Risk Factors |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D020521 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Stroke |
| mesh[14].qualifier_ui | Q000401 |
| mesh[14].descriptor_ui | D020521 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | mortality |
| mesh[14].descriptor_name | Stroke |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D014481 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | United States |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D000368 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Aged |
| mesh[17].qualifier_ui | Q000187 |
| mesh[17].descriptor_ui | D008078 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | drug effects |
| mesh[17].descriptor_name | Cholesterol, LDL |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D004311 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Double-Blind Method |
| mesh[19].qualifier_ui | Q000031 |
| mesh[19].descriptor_ui | D015118 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | analogs & derivatives |
| mesh[19].descriptor_name | Eicosapentaenoic Acid |
| mesh[20].qualifier_ui | Q000494 |
| mesh[20].descriptor_ui | D015118 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | pharmacology |
| mesh[20].descriptor_name | Eicosapentaenoic Acid |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D005260 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Female |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D006801 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Humans |
| mesh[23].qualifier_ui | Q000627 |
| mesh[23].descriptor_ui | D019161 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | therapeutic use |
| mesh[23].descriptor_name | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D008297 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Male |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D008875 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Middle Aged |
| mesh[26].qualifier_ui | Q000188 |
| mesh[26].descriptor_ui | D009203 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | drug therapy |
| mesh[26].descriptor_name | Myocardial Infarction |
| mesh[27].qualifier_ui | Q000401 |
| mesh[27].descriptor_ui | D009203 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | mortality |
| mesh[27].descriptor_name | Myocardial Infarction |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D012307 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Risk Factors |
| mesh[29].qualifier_ui | Q000188 |
| mesh[29].descriptor_ui | D020521 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | drug therapy |
| mesh[29].descriptor_name | Stroke |
| mesh[30].qualifier_ui | Q000401 |
| mesh[30].descriptor_ui | D020521 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | mortality |
| mesh[30].descriptor_name | Stroke |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D014481 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | United States |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D000368 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Aged |
| mesh[33].qualifier_ui | Q000187 |
| mesh[33].descriptor_ui | D008078 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | drug effects |
| mesh[33].descriptor_name | Cholesterol, LDL |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D004311 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Double-Blind Method |
| mesh[35].qualifier_ui | Q000031 |
| mesh[35].descriptor_ui | D015118 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | analogs & derivatives |
| mesh[35].descriptor_name | Eicosapentaenoic Acid |
| mesh[36].qualifier_ui | Q000494 |
| mesh[36].descriptor_ui | D015118 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | pharmacology |
| mesh[36].descriptor_name | Eicosapentaenoic Acid |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D005260 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Female |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D006801 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Humans |
| mesh[39].qualifier_ui | Q000627 |
| mesh[39].descriptor_ui | D019161 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | therapeutic use |
| mesh[39].descriptor_name | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D008297 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Male |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D008875 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Middle Aged |
| mesh[42].qualifier_ui | Q000188 |
| mesh[42].descriptor_ui | D009203 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | drug therapy |
| mesh[42].descriptor_name | Myocardial Infarction |
| mesh[43].qualifier_ui | Q000401 |
| mesh[43].descriptor_ui | D009203 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | mortality |
| mesh[43].descriptor_name | Myocardial Infarction |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D012307 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Risk Factors |
| mesh[45].qualifier_ui | Q000188 |
| mesh[45].descriptor_ui | D020521 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | drug therapy |
| mesh[45].descriptor_name | Stroke |
| mesh[46].qualifier_ui | Q000401 |
| mesh[46].descriptor_ui | D020521 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | mortality |
| mesh[46].descriptor_name | Stroke |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D014481 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | United States |
| type | article |
| title | REDUCE-IT USA |
| biblio.issue | 5 |
| biblio.volume | 141 |
| biblio.last_page | 375 |
| biblio.first_page | 367 |
| topics[0].id | https://openalex.org/T10394 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9993000030517578 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Lipoproteins and Cardiovascular Health |
| topics[1].id | https://openalex.org/T10027 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9932000041007996 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2712 |
| topics[1].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[1].display_name | Diabetes, Cardiovascular Risks, and Lipoproteins |
| topics[2].id | https://openalex.org/T10387 |
| topics[2].field.id | https://openalex.org/fields/29 |
| topics[2].field.display_name | Nursing |
| topics[2].score | 0.991100013256073 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2916 |
| topics[2].subfield.display_name | Nutrition and Dietetics |
| topics[2].display_name | Fatty Acid Research and Health |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9652109146118164 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C207103383 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7320607304573059 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[1].display_name | Hazard ratio |
| concepts[2].id | https://openalex.org/C500558357 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6606354117393494 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q12152 |
| concepts[2].display_name | Myocardial infarction |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6437705159187317 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C27081682 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5584288239479065 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q269829 |
| concepts[4].display_name | Placebo |
| concepts[5].id | https://openalex.org/C2777785093 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5187783241271973 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2032041 |
| concepts[5].display_name | Unstable angina |
| concepts[6].id | https://openalex.org/C2780645631 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5039059519767761 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q671554 |
| concepts[6].display_name | Stroke (engine) |
| concepts[7].id | https://openalex.org/C555293320 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4835509955883026 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[7].display_name | Diabetes mellitus |
| concepts[8].id | https://openalex.org/C203092338 |
| concepts[8].level | 3 |
| concepts[8].score | 0.4625164270401001 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1340863 |
| concepts[8].display_name | Clinical endpoint |
| concepts[9].id | https://openalex.org/C164705383 |
| concepts[9].level | 1 |
| concepts[9].score | 0.43708986043930054 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q10379 |
| concepts[9].display_name | Cardiology |
| concepts[10].id | https://openalex.org/C168563851 |
| concepts[10].level | 2 |
| concepts[10].score | 0.41308704018592834 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[10].display_name | Randomized controlled trial |
| concepts[11].id | https://openalex.org/C44249647 |
| concepts[11].level | 2 |
| concepts[11].score | 0.24951690435409546 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[11].display_name | Confidence interval |
| concepts[12].id | https://openalex.org/C134018914 |
| concepts[12].level | 1 |
| concepts[12].score | 0.1274431049823761 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[12].display_name | Endocrinology |
| concepts[13].id | https://openalex.org/C204787440 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[13].display_name | Alternative medicine |
| concepts[14].id | https://openalex.org/C78519656 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q101333 |
| concepts[14].display_name | Mechanical engineering |
| concepts[15].id | https://openalex.org/C127413603 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q11023 |
| concepts[15].display_name | Engineering |
| concepts[16].id | https://openalex.org/C142724271 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[16].display_name | Pathology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9652109146118164 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/hazard-ratio |
| keywords[1].score | 0.7320607304573059 |
| keywords[1].display_name | Hazard ratio |
| keywords[2].id | https://openalex.org/keywords/myocardial-infarction |
| keywords[2].score | 0.6606354117393494 |
| keywords[2].display_name | Myocardial infarction |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.6437705159187317 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/placebo |
| keywords[4].score | 0.5584288239479065 |
| keywords[4].display_name | Placebo |
| keywords[5].id | https://openalex.org/keywords/unstable-angina |
| keywords[5].score | 0.5187783241271973 |
| keywords[5].display_name | Unstable angina |
| keywords[6].id | https://openalex.org/keywords/stroke |
| keywords[6].score | 0.5039059519767761 |
| keywords[6].display_name | Stroke (engine) |
| keywords[7].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[7].score | 0.4835509955883026 |
| keywords[7].display_name | Diabetes mellitus |
| keywords[8].id | https://openalex.org/keywords/clinical-endpoint |
| keywords[8].score | 0.4625164270401001 |
| keywords[8].display_name | Clinical endpoint |
| keywords[9].id | https://openalex.org/keywords/cardiology |
| keywords[9].score | 0.43708986043930054 |
| keywords[9].display_name | Cardiology |
| keywords[10].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[10].score | 0.41308704018592834 |
| keywords[10].display_name | Randomized controlled trial |
| keywords[11].id | https://openalex.org/keywords/confidence-interval |
| keywords[11].score | 0.24951690435409546 |
| keywords[11].display_name | Confidence interval |
| keywords[12].id | https://openalex.org/keywords/endocrinology |
| keywords[12].score | 0.1274431049823761 |
| keywords[12].display_name | Endocrinology |
| language | en |
| locations[0].id | doi:10.1161/circulationaha.119.044440 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S116251202 |
| locations[0].source.issn | 0009-7322, 1524-4539 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0009-7322 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Circulation |
| locations[0].source.host_organization | https://openalex.org/P4310315671 |
| locations[0].source.host_organization_name | Lippincott Williams & Wilkins |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| locations[0].source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| locations[0].license | |
| locations[0].pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044440 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Circulation |
| locations[0].landing_page_url | https://doi.org/10.1161/circulationaha.119.044440 |
| locations[1].id | pmid:31707829 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Circulation |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/31707829 |
| locations[2].id | pmh:oai:escholarship.org:ark:/13030/qt3bk0760k |
| locations[2].is_oa | True |
| locations[2].source | |
| locations[2].license | cc-by-nc-nd |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Circulation, vol 141, iss 5 |
| locations[2].landing_page_url | https://escholarship.org/uc/item/3bk0760k |
| locations[3].id | pmh:oai:europepmc.org:5967384 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7004453 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5010571732 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1278-6245 |
| authorships[0].author.display_name | Deepak L. Bhatt |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1283280774, https://openalex.org/I136199984 |
| authorships[0].affiliations[0].raw_affiliation_string | Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B.). |
| authorships[0].institutions[0].id | https://openalex.org/I1283280774 |
| authorships[0].institutions[0].ror | https://ror.org/04b6nzv94 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1283280774, https://openalex.org/I48633490 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Brigham and Women's Hospital |
| authorships[0].institutions[1].id | https://openalex.org/I136199984 |
| authorships[0].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | Harvard University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Deepak L. Bhatt |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B.). |
| authorships[1].author.id | https://openalex.org/A5015234811 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-1679-2095 |
| authorships[1].author.display_name | Michael Miller |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I126744593 |
| authorships[1].affiliations[0].raw_affiliation_string | Michael Miller Department of Medicine, University of Maryland School of Medicine, Baltimore (M.M.). |
| authorships[1].institutions[0].id | https://openalex.org/I126744593 |
| authorships[1].institutions[0].ror | https://ror.org/04rq5mt64 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I126744593 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | University of Maryland, Baltimore |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Michael Miller |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Michael Miller Department of Medicine, University of Maryland School of Medicine, Baltimore (M.M.). |
| authorships[2].author.id | https://openalex.org/A5020230532 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-9807-4010 |
| authorships[2].author.display_name | Eliot A. Brinton |
| authorships[2].affiliations[0].raw_affiliation_string | Eliot A. Brinton Utah Lipid Center, Salt Lake City (E.A.B.). |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Eliot A. Brinton |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Eliot A. Brinton Utah Lipid Center, Salt Lake City (E.A.B.). |
| authorships[3].author.id | https://openalex.org/A5084230583 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-9926-2179 |
| authorships[3].author.display_name | Terry A. Jacobson |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I150468666, https://openalex.org/I4210150894 |
| authorships[3].affiliations[0].raw_affiliation_string | Terry A. Jacobson Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA (T.A.J.). |
| authorships[3].institutions[0].id | https://openalex.org/I150468666 |
| authorships[3].institutions[0].ror | https://ror.org/03czfpz43 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I150468666 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Emory University |
| authorships[3].institutions[1].id | https://openalex.org/I4210150894 |
| authorships[3].institutions[1].ror | https://ror.org/05pmj3x43 |
| authorships[3].institutions[1].type | company |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210150894 |
| authorships[3].institutions[1].country_code | US |
| authorships[3].institutions[1].display_name | Jacobs (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Terry A. Jacobson |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Terry A. Jacobson Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA (T.A.J.). |
| authorships[4].author.id | https://openalex.org/A5003831287 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6896-2941 |
| authorships[4].author.display_name | Philippe Gabríel Steg |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210145170, https://openalex.org/I4210166751 |
| authorships[4].affiliations[0].raw_affiliation_string | French Alliance for Cardiovascular Trials, Hôpital Bichat, Paris, France (P.G.S.). |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I154526488, https://openalex.org/I204730241, https://openalex.org/I4210097159 |
| authorships[4].affiliations[1].raw_affiliation_string | Assistance Publique-Hôpitaux de Paris, Université de Paris, INSERM Unité 1148, Paris, France (P.G.S.). |
| authorships[4].institutions[0].id | https://openalex.org/I4210166751 |
| authorships[4].institutions[0].ror | https://ror.org/05g3p2p60 |
| authorships[4].institutions[0].type | government |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210166751 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Alliance nationale pour les sciences de la vie et de la santé |
| authorships[4].institutions[1].id | https://openalex.org/I4210097159 |
| authorships[4].institutions[1].ror | https://ror.org/00pg5jh14 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I4210097159 |
| authorships[4].institutions[1].country_code | FR |
| authorships[4].institutions[1].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[4].institutions[2].id | https://openalex.org/I4210145170 |
| authorships[4].institutions[2].ror | https://ror.org/03fdnmv92 |
| authorships[4].institutions[2].type | healthcare |
| authorships[4].institutions[2].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210145170 |
| authorships[4].institutions[2].country_code | FR |
| authorships[4].institutions[2].display_name | Hôpital Bichat-Claude-Bernard |
| authorships[4].institutions[3].id | https://openalex.org/I154526488 |
| authorships[4].institutions[3].ror | https://ror.org/02vjkv261 |
| authorships[4].institutions[3].type | government |
| authorships[4].institutions[3].lineage | https://openalex.org/I154526488 |
| authorships[4].institutions[3].country_code | FR |
| authorships[4].institutions[3].display_name | Inserm |
| authorships[4].institutions[4].id | https://openalex.org/I204730241 |
| authorships[4].institutions[4].ror | https://ror.org/05f82e368 |
| authorships[4].institutions[4].type | education |
| authorships[4].institutions[4].lineage | https://openalex.org/I204730241 |
| authorships[4].institutions[4].country_code | FR |
| authorships[4].institutions[4].display_name | Université Paris Cité |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Ph. Gabriel Steg |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Assistance Publique-Hôpitaux de Paris, Université de Paris, INSERM Unité 1148, Paris, France (P.G.S.)., French Alliance for Cardiovascular Trials, Hôpital Bichat, Paris, France (P.G.S.). |
| authorships[5].author.id | https://openalex.org/A5061372345 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-9302-4743 |
| authorships[5].author.display_name | Steven B. Ketchum |
| authorships[5].affiliations[0].raw_affiliation_string | Steven B. Ketchum Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Steven B. Ketchum |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Steven B. Ketchum Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[6].author.id | https://openalex.org/A5012896274 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Ralph T. Doyle |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210130338 |
| authorships[6].affiliations[0].raw_affiliation_string | Ralph T. Doyle Jr Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[6].institutions[0].id | https://openalex.org/I4210130338 |
| authorships[6].institutions[0].ror | https://ror.org/0353d6x38 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210113585, https://openalex.org/I4210130338 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Amarin (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ralph T. Doyle |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Ralph T. Doyle Jr Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[7].author.id | https://openalex.org/A5072532905 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-3714-6084 |
| authorships[7].author.display_name | Rebecca A. Juliano |
| authorships[7].affiliations[0].raw_affiliation_string | Rebecca A. Juliano Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Rebecca A. Juliano |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Rebecca A. Juliano Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[8].author.id | https://openalex.org/A5055540639 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-7003-4925 |
| authorships[8].author.display_name | Lixia Jiao |
| authorships[8].affiliations[0].raw_affiliation_string | Lixia Jiao Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Lixia Jiao |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Lixia Jiao Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[9].author.id | https://openalex.org/A5090144198 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-1533-3679 |
| authorships[9].author.display_name | Craig Granowitz |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210130338 |
| authorships[9].affiliations[0].raw_affiliation_string | Craig Granowitz Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[9].institutions[0].id | https://openalex.org/I4210130338 |
| authorships[9].institutions[0].ror | https://ror.org/0353d6x38 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210113585, https://openalex.org/I4210130338 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Amarin (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Craig Granowitz |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Craig Granowitz Amarin Pharma, Inc., Bridgewater, NJ (S.B.K., R.T.D., R.A.J., L.J., C.G.). |
| authorships[10].author.id | https://openalex.org/A5049309607 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-8200-8983 |
| authorships[10].author.display_name | Jean‐Claude Tardif |
| authorships[10].countries | CA |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2800290161, https://openalex.org/I70931966 |
| authorships[10].affiliations[0].raw_affiliation_string | Montreal Heart Institute, Université de Montréal, Quebec, Canada (J.-C.T.). |
| authorships[10].institutions[0].id | https://openalex.org/I2800290161 |
| authorships[10].institutions[0].ror | https://ror.org/03vs03g62 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I2800290161 |
| authorships[10].institutions[0].country_code | CA |
| authorships[10].institutions[0].display_name | Montreal Heart Institute |
| authorships[10].institutions[1].id | https://openalex.org/I70931966 |
| authorships[10].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[10].institutions[1].type | education |
| authorships[10].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[10].institutions[1].country_code | CA |
| authorships[10].institutions[1].display_name | Université de Montréal |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Jean-Claude Tardif |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Montreal Heart Institute, Université de Montréal, Quebec, Canada (J.-C.T.). |
| authorships[11].author.id | https://openalex.org/A5030434846 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-6044-045X |
| authorships[11].author.display_name | Brian Olshansky |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I126307644 |
| authorships[11].affiliations[0].raw_affiliation_string | Brian Olshansky University of Iowa, Iowa City (B.O.). |
| authorships[11].institutions[0].id | https://openalex.org/I126307644 |
| authorships[11].institutions[0].ror | https://ror.org/036jqmy94 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I126307644 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | University of Iowa |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Brian Olshansky |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Brian Olshansky University of Iowa, Iowa City (B.O.). |
| authorships[12].author.id | https://openalex.org/A5084723768 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Mina K. Chung |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I1316902750 |
| authorships[12].affiliations[0].raw_affiliation_string | Mina K. Chung Cleveland Clinic, OH (M.K.C.). |
| authorships[12].institutions[0].id | https://openalex.org/I1316902750 |
| authorships[12].institutions[0].ror | https://ror.org/03xjacd83 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I1316902750 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Cleveland Clinic |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Mina K. Chung |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Mina K. Chung Cleveland Clinic, OH (M.K.C.). |
| authorships[13].author.id | https://openalex.org/A5007026783 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-4857-9125 |
| authorships[13].author.display_name | C. Michael Gibson |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I2801337628, https://openalex.org/I4210111520 |
| authorships[13].affiliations[0].raw_affiliation_string | C. Michael Gibson Beth Israel Deaconess Hospital, Boston, MA (C.M.G.). Baim Clinical Research Institute, Boston, MA (C.M.G.). |
| authorships[13].affiliations[1].institution_ids | https://openalex.org/I4210111520 |
| authorships[13].affiliations[1].raw_affiliation_string | Baim Clinical Research Institute, Boston, MA (C.M.G.). |
| authorships[13].institutions[0].id | https://openalex.org/I4210111520 |
| authorships[13].institutions[0].ror | https://ror.org/01va8fr66 |
| authorships[13].institutions[0].type | nonprofit |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210111520 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Baim Institute for Clinical Research |
| authorships[13].institutions[1].id | https://openalex.org/I2801337628 |
| authorships[13].institutions[1].ror | https://ror.org/02cpjkp59 |
| authorships[13].institutions[1].type | healthcare |
| authorships[13].institutions[1].lineage | https://openalex.org/I2801337628 |
| authorships[13].institutions[1].country_code | US |
| authorships[13].institutions[1].display_name | Beth Israel Deaconess Hospital |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | C. Michael Gibson |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Baim Clinical Research Institute, Boston, MA (C.M.G.)., C. Michael Gibson Beth Israel Deaconess Hospital, Boston, MA (C.M.G.). Baim Clinical Research Institute, Boston, MA (C.M.G.). |
| authorships[14].author.id | https://openalex.org/A5045665978 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-4110-7675 |
| authorships[14].author.display_name | Robert P. Giugliano |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I1283280774, https://openalex.org/I136199984 |
| authorships[14].affiliations[0].raw_affiliation_string | Robert P. Giugliano Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.P.G.). |
| authorships[14].institutions[0].id | https://openalex.org/I1283280774 |
| authorships[14].institutions[0].ror | https://ror.org/04b6nzv94 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I1283280774, https://openalex.org/I48633490 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Brigham and Women's Hospital |
| authorships[14].institutions[1].id | https://openalex.org/I136199984 |
| authorships[14].institutions[1].ror | https://ror.org/03vek6s52 |
| authorships[14].institutions[1].type | education |
| authorships[14].institutions[1].lineage | https://openalex.org/I136199984 |
| authorships[14].institutions[1].country_code | US |
| authorships[14].institutions[1].display_name | Harvard University |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Robert P. Giugliano |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Robert P. Giugliano Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.P.G.). |
| authorships[15].author.id | https://openalex.org/A5079665496 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-9616-1946 |
| authorships[15].author.display_name | Matthew J. Budoff |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I177607063, https://openalex.org/I2801403999, https://openalex.org/I4210165985 |
| authorships[15].affiliations[0].raw_affiliation_string | Matthew J. Budoff Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA (M.J.B.). |
| authorships[15].institutions[0].id | https://openalex.org/I4210165985 |
| authorships[15].institutions[0].ror | https://ror.org/05h4zj272 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I1328359107, https://openalex.org/I4210165985 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Harbor–UCLA Medical Center |
| authorships[15].institutions[1].id | https://openalex.org/I177607063 |
| authorships[15].institutions[1].ror | https://ror.org/025j2nd68 |
| authorships[15].institutions[1].type | nonprofit |
| authorships[15].institutions[1].lineage | https://openalex.org/I177607063 |
| authorships[15].institutions[1].country_code | US |
| authorships[15].institutions[1].display_name | The Lundquist Institute |
| authorships[15].institutions[2].id | https://openalex.org/I2801403999 |
| authorships[15].institutions[2].ror | https://ror.org/04vq5kb54 |
| authorships[15].institutions[2].type | healthcare |
| authorships[15].institutions[2].lineage | https://openalex.org/I2799798094, https://openalex.org/I2801403999 |
| authorships[15].institutions[2].country_code | US |
| authorships[15].institutions[2].display_name | UCLA Medical Center |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Matthew J. Budoff |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Matthew J. Budoff Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA (M.J.B.). |
| authorships[16].author.id | https://openalex.org/A5052604218 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-6432-1730 |
| authorships[16].author.display_name | Christie M. Ballantyne |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I181547552 |
| authorships[16].affiliations[0].raw_affiliation_string | Christie M. Ballantyne Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.). |
| authorships[16].institutions[0].id | https://openalex.org/I181547552 |
| authorships[16].institutions[0].ror | https://ror.org/02pttbw34 |
| authorships[16].institutions[0].type | education |
| authorships[16].institutions[0].lineage | https://openalex.org/I181547552, https://openalex.org/I2801539370 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | Baylor College of Medicine |
| authorships[16].author_position | last |
| authorships[16].raw_author_name | Christie M. Ballantyne |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Christie M. Ballantyne Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.). |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044440 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2019-11-22T00:00:00 |
| display_name | REDUCE-IT USA |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10394 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9993000030517578 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Lipoproteins and Cardiovascular Health |
| related_works | https://openalex.org/W1859326399, https://openalex.org/W2085650940, https://openalex.org/W1966127473, https://openalex.org/W2169836118, https://openalex.org/W2081991953, https://openalex.org/W2025729332, https://openalex.org/W1974781192, https://openalex.org/W2075173650, https://openalex.org/W2108737548, https://openalex.org/W2349356359 |
| cited_by_count | 132 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 11 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 16 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 17 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 23 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 25 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 37 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 2 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1161/circulationaha.119.044440 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S116251202 |
| best_oa_location.source.issn | 0009-7322, 1524-4539 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0009-7322 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Circulation |
| best_oa_location.source.host_organization | https://openalex.org/P4310315671 |
| best_oa_location.source.host_organization_name | Lippincott Williams & Wilkins |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| best_oa_location.source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044440 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Circulation |
| best_oa_location.landing_page_url | https://doi.org/10.1161/circulationaha.119.044440 |
| primary_location.id | doi:10.1161/circulationaha.119.044440 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S116251202 |
| primary_location.source.issn | 0009-7322, 1524-4539 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0009-7322 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Circulation |
| primary_location.source.host_organization | https://openalex.org/P4310315671 |
| primary_location.source.host_organization_name | Lippincott Williams & Wilkins |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| primary_location.source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| primary_location.license | |
| primary_location.pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.119.044440 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Circulation |
| primary_location.landing_page_url | https://doi.org/10.1161/circulationaha.119.044440 |
| publication_date | 2019-11-11 |
| publication_year | 2019 |
| referenced_works | https://openalex.org/W2808724025, https://openalex.org/W2911290113, https://openalex.org/W2970436550, https://openalex.org/W2899669642, https://openalex.org/W2920910705, https://openalex.org/W2969391566, https://openalex.org/W2978852271, https://openalex.org/W2980777290, https://openalex.org/W2948369279, https://openalex.org/W4213222556, https://openalex.org/W2969523838, https://openalex.org/W3183857127, https://openalex.org/W2987000681, https://openalex.org/W2916068410, https://openalex.org/W2902364078, https://openalex.org/W2987665527, https://openalex.org/W2936852091, https://openalex.org/W2140501627, https://openalex.org/W2085260510, https://openalex.org/W2430995757, https://openalex.org/W2103443725, https://openalex.org/W55307716, https://openalex.org/W2038039359, https://openalex.org/W2077443075, https://openalex.org/W2099877908, https://openalex.org/W133383503, https://openalex.org/W1549769145, https://openalex.org/W2006790325, https://openalex.org/W2104011674, https://openalex.org/W2298215063, https://openalex.org/W2104209472, https://openalex.org/W2598498016 |
| referenced_works_count | 32 |
| abstract_inverted_index.- | 31 |
| abstract_inverted_index.. | 329 |
| abstract_inverted_index.4 | 83 |
| abstract_inverted_index.A | 122, 135 |
| abstract_inverted_index.P | 186, 204, 227, 239, 250, 263, 274 |
| abstract_inverted_index.a | 73, 150, 313 |
| abstract_inverted_index.US | 139, 270, 305 |
| abstract_inverted_index.in | 47, 168, 195, 268, 296 |
| abstract_inverted_index.of | 25, 42, 44, 75, 128, 137, 142, 152, 170, 175, 315 |
| abstract_inverted_index.or | 77, 85, 102, 119 |
| abstract_inverted_index.to | 38, 80, 220, 232, 243, 256 |
| abstract_inverted_index.4.9 | 153 |
| abstract_inverted_index.All | 206 |
| abstract_inverted_index.CI, | 184, 202, 225, 237, 248, 261 |
| abstract_inverted_index.HR, | 222, 234, 245, 258 |
| abstract_inverted_index.The | 87, 107, 162 |
| abstract_inverted_index.and | 61, 64, 69, 72, 130, 147, 158, 213, 252, 278, 299, 317 |
| abstract_inverted_index.end | 90, 111, 132, 165, 192, 209, 302, 319 |
| abstract_inverted_index.for | 104, 126, 149, 265 |
| abstract_inverted_index.g/d | 84 |
| abstract_inverted_index.key | 108, 189, 300 |
| abstract_inverted_index.the | 8, 18, 40, 48, 143, 188, 269, 284, 290, 297, 304 |
| abstract_inverted_index.was | 36, 92, 113, 124 |
| abstract_inverted_index.(HR, | 199 |
| abstract_inverted_index.0.63 | 246 |
| abstract_inverted_index.0.66 | 223 |
| abstract_inverted_index.0.69 | 182, 200 |
| abstract_inverted_index.0.70 | 259 |
| abstract_inverted_index.0.72 | 235 |
| abstract_inverted_index.3146 | 138 |
| abstract_inverted_index.8179 | 54 |
| abstract_inverted_index.9.7% | 159 |
| abstract_inverted_index.Some | 1 |
| abstract_inverted_index.This | 21 |
| abstract_inverted_index.URL: | 327 |
| abstract_inverted_index.[95% | 183, 201, 224, 236, 247, 260 |
| abstract_inverted_index.from | 7 |
| abstract_inverted_index.full | 285 |
| abstract_inverted_index.have | 3 |
| abstract_inverted_index.less | 12 |
| abstract_inverted_index.risk | 310 |
| abstract_inverted_index.than | 14 |
| abstract_inverted_index.that | 5 |
| abstract_inverted_index.were | 145, 156, 160, 211, 281 |
| abstract_inverted_index.with | 28, 57, 283 |
| abstract_inverted_index.(4.1% | 242 |
| abstract_inverted_index.(6.7% | 219 |
| abstract_inverted_index.(8.8% | 231 |
| abstract_inverted_index.(9.8% | 255 |
| abstract_inverted_index.12.1% | 198 |
| abstract_inverted_index.16.6% | 196 |
| abstract_inverted_index.18.2% | 174 |
| abstract_inverted_index.2.6%; | 244 |
| abstract_inverted_index.24.7% | 169 |
| abstract_inverted_index.32.3% | 155 |
| abstract_inverted_index.4.7%; | 221 |
| abstract_inverted_index.6.7%; | 233 |
| abstract_inverted_index.7.2%; | 257 |
| abstract_inverted_index.Ethyl | 30 |
| abstract_inverted_index.Trial | 325 |
| abstract_inverted_index.[HR], | 181 |
| abstract_inverted_index.death | 218 |
| abstract_inverted_index.ethyl | 46, 82 |
| abstract_inverted_index.found | 4 |
| abstract_inverted_index.mg/dL | 63, 71 |
| abstract_inverted_index.point | 91, 112, 166, 193 |
| abstract_inverted_index.ratio | 180 |
| abstract_inverted_index.study | 286 |
| abstract_inverted_index.total | 136 |
| abstract_inverted_index.women | 157 |
| abstract_inverted_index.>40 | 68 |
| abstract_inverted_index.(38.5% | 141 |
| abstract_inverted_index.=0.02. | 276 |
| abstract_inverted_index.Events | 27 |
| abstract_inverted_index.Safety | 277 |
| abstract_inverted_index.States | 10 |
| abstract_inverted_index.Trial) | 33 |
| abstract_inverted_index.Unique | 330 |
| abstract_inverted_index.United | 9, 19, 49 |
| abstract_inverted_index.across | 312 |
| abstract_inverted_index.death, | 94, 115 |
| abstract_inverted_index.degree | 41 |
| abstract_inverted_index.derive | 11 |
| abstract_inverted_index.median | 151 |
| abstract_inverted_index.non-US | 272, 291 |
| abstract_inverted_index.points | 210 |
| abstract_inverted_index.robust | 309 |
| abstract_inverted_index.showed | 293 |
| abstract_inverted_index.stroke | 241 |
| abstract_inverted_index.trial) | 144 |
| abstract_inverted_index.trials | 2 |
| abstract_inverted_index.versus | 173, 197, 271 |
| abstract_inverted_index.years; | 154 |
| abstract_inverted_index.≤100 | 70 |
| abstract_inverted_index.≥135 | 60 |
| abstract_inverted_index.<500 | 62 |
| abstract_inverted_index.(hazard | 179 |
| abstract_inverted_index.=0.01), | 240 |
| abstract_inverted_index.=0.02), | 251 |
| abstract_inverted_index.States. | 20, 50 |
| abstract_inverted_index.Whereas | 289 |
| abstract_inverted_index.angina. | 106 |
| abstract_inverted_index.benefit | 13, 43 |
| abstract_inverted_index.cohort. | 287 |
| abstract_inverted_index.history | 74 |
| abstract_inverted_index.outside | 17 |
| abstract_inverted_index.points, | 303, 320 |
| abstract_inverted_index.points. | 133 |
| abstract_inverted_index.primary | 88, 163, 298 |
| abstract_inverted_index.stroke, | 99 |
| abstract_inverted_index.stroke. | 121 |
| abstract_inverted_index.variety | 314 |
| abstract_inverted_index.=0.004); | 264 |
| abstract_inverted_index.=0.007), | 228 |
| abstract_inverted_index.Clinical | 324 |
| abstract_inverted_index.Methods: | 51 |
| abstract_inverted_index.Results: | 134 |
| abstract_inverted_index.analysis | 35 |
| abstract_inverted_index.coronary | 100 |
| abstract_inverted_index.diabetes | 78 |
| abstract_inverted_index.enrolled | 16 |
| abstract_inverted_index.findings | 280 |
| abstract_inverted_index.followed | 148 |
| abstract_inverted_index.mellitus | 79 |
| abstract_inverted_index.nonfatal | 95, 98, 116, 120 |
| abstract_inverted_index.occurred | 167, 194 |
| abstract_inverted_index.patients | 6, 15, 56, 140, 172, 178 |
| abstract_inverted_index.placebo. | 86 |
| abstract_inverted_index.reduced, | 215 |
| abstract_inverted_index.subgroup | 34, 292, 306 |
| abstract_inverted_index.unstable | 105 |
| abstract_inverted_index.Hispanic. | 161 |
| abstract_inverted_index.Icosapent | 29 |
| abstract_inverted_index.REDUCE-IT | 23, 52 |
| abstract_inverted_index.all-cause | 253, 266, 322 |
| abstract_inverted_index.composite | 89, 110, 131, 164, 191, 318 |
| abstract_inverted_index.conducted | 37 |
| abstract_inverted_index.determine | 39 |
| abstract_inverted_index.hierarchy | 123 |
| abstract_inverted_index.icosapent | 45, 81, 176 |
| abstract_inverted_index.including | 216, 321 |
| abstract_inverted_index.mortality | 254, 267 |
| abstract_inverted_index.patients, | 273 |
| abstract_inverted_index.secondary | 109, 190, 301 |
| abstract_inverted_index.(Reduction | 24 |
| abstract_inverted_index.=0.00008). | 205 |
| abstract_inverted_index.consistent | 282 |
| abstract_inverted_index.individual | 129, 316 |
| abstract_inverted_index.infarction | 230 |
| abstract_inverted_index.mortality. | 323 |
| abstract_inverted_index.myocardial | 96, 117, 229 |
| abstract_inverted_index.qualifying | 58 |
| abstract_inverted_index.randomized | 53, 146 |
| abstract_inverted_index.reductions | 295, 311 |
| abstract_inverted_index.=0.000001); | 187 |
| abstract_inverted_index.Background: | 0 |
| abstract_inverted_index.cholesterol | 67 |
| abstract_inverted_index.examination | 127 |
| abstract_inverted_index.identifier: | 331 |
| abstract_inverted_index.infarction, | 97, 118 |
| abstract_inverted_index.interaction | 275 |
| abstract_inverted_index.lipoprotein | 66 |
| abstract_inverted_index.low-density | 65 |
| abstract_inverted_index.significant | 294 |
| abstract_inverted_index.Conclusions: | 288 |
| abstract_inverted_index.Intervention | 32 |
| abstract_inverted_index.NCT01492361. | 332 |
| abstract_inverted_index.demonstrated | 307 |
| abstract_inverted_index.hierarchical | 208 |
| abstract_inverted_index.meaningfully | 212 |
| abstract_inverted_index.particularly | 308 |
| abstract_inverted_index.prespecified | 22, 125, 207 |
| abstract_inverted_index.tolerability | 279 |
| abstract_inverted_index.0.43–0.93]; | 249 |
| abstract_inverted_index.0.49–0.90]; | 226 |
| abstract_inverted_index.0.55–0.90]; | 262 |
| abstract_inverted_index.0.56–0.93]; | 238 |
| abstract_inverted_index.0.57–0.83]; | 203 |
| abstract_inverted_index.0.59–0.80]; | 185 |
| abstract_inverted_index.Registration: | 326 |
| abstract_inverted_index.ethyl-treated | 177 |
| abstract_inverted_index.significantly | 214 |
| abstract_inverted_index.triglycerides | 59 |
| abstract_inverted_index.Cardiovascular | 26 |
| abstract_inverted_index.cardiovascular | 93, 114, 217 |
| abstract_inverted_index.statin-treated | 55 |
| abstract_inverted_index.atherosclerosis | 76 |
| abstract_inverted_index.hospitalization | 103 |
| abstract_inverted_index.placebo-treated | 171 |
| abstract_inverted_index.revascularization, | 101 |
| abstract_inverted_index.https://www.clinicaltrials.gov | 328 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 94 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 17 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8500000238418579 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.99653556 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |